Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing.

Bansode V, McCormack GP, Crampin AC, Ngwira B, Shrestha RK, French N, Glynn JR, Travers SA.

BMC Infect Dis. 2013 Jan 30;13:52. doi: 10.1186/1471-2334-13-52.

2.

Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco.

El Annaz H, Recordon-Pinson P, Tagajdid R, Doblali T, Belefquih B, Oumakhir S, Sedrati O, Mrani S, Fleury H.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):944-8. doi: 10.1089/AID.2011.0278. Epub 2011 Nov 23.

3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.

Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, Arnold TE, Lataillade M.

Antivir Ther. 2011;16(6):925-9. doi: 10.3851/IMP1851.

PMID:
21900725
5.

Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal MJ.

PLoS One. 2009 Jun 29;4(6):e6079. doi: 10.1371/journal.pone.0006079.

6.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

7.

Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1.

Handema R, Terunuma H, Kasolo F, Kasai H, Sichone M, Yamashita A, Deng X, Mulundu G, Ichiyama K, Munkanta M, Yokota T, Wakasugi N, Tezuka F, Yamamoto N, Ito M.

AIDS Res Hum Retroviruses. 2003 Feb;19(2):151-60.

PMID:
12643279
8.

Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.

Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, Bonnet F, Lazaro E, Neau D, Fleury H, Dabis F, Morlat P, Masquelier B.

PLoS One. 2014 Jan 27;9(1):e86771. doi: 10.1371/journal.pone.0086771. eCollection 2014.

9.

Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St John E, Moreno E, Kozal M.

PLoS One. 2012;7(2):e30118. doi: 10.1371/journal.pone.0030118. Epub 2012 Feb 15.

10.

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.

Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M.

AIDS. 2011 Nov 13;25(17):2183-8. doi: 10.1097/QAD.0b013e32834bbbe9.

PMID:
21860346
11.

HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China.

Chen X, Zou X, He J, Zheng J, Chiarella J, Kozal MJ.

PLoS One. 2016 Feb 19;11(2):e0149215. doi: 10.1371/journal.pone.0149215. eCollection 2016.

12.

Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.

Torti C, Moretti F, Uccelli MC, Tirelli V, Quiros-Roldan E, Gargiulo F, Carosi G.

Med Sci Monit. 2003 Apr;9(4):CS16-9.

PMID:
12709675
13.

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.

Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W.

PLoS Med. 2008 Jul 29;5(7):e158. doi: 10.1371/journal.pmed.0050158.

14.

Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.

Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V, Dal Bello F, Franchin E, Franzetti M, Rossi MC, Cattelan AM, Romano L, Zazzi M, Andreoni M, Palù G.

J Clin Microbiol. 2007 Jun;45(6):1783-8. Epub 2007 Apr 18. Erratum in: J Clin Microbiol. 2007 Oct;45(10):3484.

15.

Proviral DNA as a Target for HIV-1 Resistance Analysis.

Lübke N, Di Cristanziano V, Sierra S, Knops E, Schülter E, Jensen B, Oette M, Lengauer T, Kaiser R.

Intervirology. 2015;58(3):184-9. doi: 10.1159/000431093. Epub 2015 Jun 27.

16.

Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.

Darwich L, Esteve A, Ruiz L, Paredes R, Bellido R, Cabrera C, Romeu J, Bofill M, Clotet B, Martinez-Picado J.

AIDS Res Hum Retroviruses. 2008 May;24(5):725-32. doi: 10.1089/aid.2007.0255.

PMID:
18462084
17.

Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.

Hauser A, Kuecherer C, Kunz A, Dabrowski PW, Radonić A, Nitsche A, Theuring S, Bannert N, Sewangi J, Mbezi P, Dugange F, Harms G, Meixenberger K.

PLoS One. 2015 Oct 15;10(10):e0140809. doi: 10.1371/journal.pone.0140809. eCollection 2015.

18.

Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations.

Pingen M, van der Ende ME, Wensing AM, el Barzouhi A, Simen BB, Schutten M, Boucher CA.

HIV Med. 2013 Mar;14(3):176-81. doi: 10.1111/j.1468-1293.2012.01037.x. Epub 2012 Sep 19.

19.

Deep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, Brazil.

Pessôa R, Watanabe JT, Calabria P, Felix AC, Loureiro P, Sabino EC, Busch MP, Sanabani SS; International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III.

PLoS One. 2014 Nov 17;9(11):e112674. doi: 10.1371/journal.pone.0112674. eCollection 2014.

20.

Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil.

Barreto CC, Nishyia A, Araújo LV, Ferreira JE, Busch MP, Sabino EC.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):338-41.

PMID:
16540943
Items per page

Supplemental Content

Write to the Help Desk